[go: up one dir, main page]

WO2006032781A3 - Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus - Google Patents

Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus Download PDF

Info

Publication number
WO2006032781A3
WO2006032781A3 PCT/FR2005/002331 FR2005002331W WO2006032781A3 WO 2006032781 A3 WO2006032781 A3 WO 2006032781A3 FR 2005002331 W FR2005002331 W FR 2005002331W WO 2006032781 A3 WO2006032781 A3 WO 2006032781A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
peptide derivatives
cells
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/002331
Other languages
English (en)
Other versions
WO2006032781A2 (fr
Inventor
Nicolas Dupin
Philippe-Alain Grange
Vincent Calvez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Descartes
Original Assignee
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Descartes filed Critical Universite Paris Descartes
Publication of WO2006032781A2 publication Critical patent/WO2006032781A2/fr
Publication of WO2006032781A3 publication Critical patent/WO2006032781A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux peptides dérivés de la lactoferrine, des anticorps et des compositions pharmaceutiques les comprenant ainsi que des kits et des méthodes de criblage de molécules actives, en particulier de molécules ayant une activité dans le traitement des infections provoquées par un herpesvirus. L'invention se rapporte également à des constructions génétiques, cellules et compositions utiles pour la mise en œuvre de telles méthodes de criblage, par exemple des cellules génétiquement modifiées pour surexprimer une partie de la lactoferrine, ainsi que les procédés de préparation desdites cellules. L'invention peut être mise en œuvre pour l'identification de composés actifs ou utilisables comme têtes de séries pour le développement de médicaments actifs pour la prise en charge de pathologies provoquées par une infection virale.
PCT/FR2005/002331 2004-09-21 2005-09-20 Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus Ceased WO2006032781A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409969A FR2875501B1 (fr) 2004-09-21 2004-09-21 Nouveaux derives peptidiques, compositions et utilisations dans un traitement therapeutique de l'infection par un herpesvirus
FR0409969 2004-09-21

Publications (2)

Publication Number Publication Date
WO2006032781A2 WO2006032781A2 (fr) 2006-03-30
WO2006032781A3 true WO2006032781A3 (fr) 2006-08-31

Family

ID=34950862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002331 Ceased WO2006032781A2 (fr) 2004-09-21 2005-09-20 Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus

Country Status (2)

Country Link
FR (1) FR2875501B1 (fr)
WO (1) WO2006032781A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869446A (en) * 1996-07-09 1999-02-09 Gambit International Limited Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections
WO2000072690A2 (fr) * 1999-05-28 2000-12-07 Naidu A Satyanarayan Agents antimicrobiens de lactoferrine immobilisee (im-lf) et utilisations associees
WO2002077239A1 (fr) * 2001-03-27 2002-10-03 Sumitomo Pharmaceuticals Company, Limited Polypeptides se liant au virus hcv
CA2485957A1 (fr) * 2002-11-29 2004-06-17 Nobuhiko Katunuma Inhibiteur de protease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869446A (en) * 1996-07-09 1999-02-09 Gambit International Limited Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections
WO2000072690A2 (fr) * 1999-05-28 2000-12-07 Naidu A Satyanarayan Agents antimicrobiens de lactoferrine immobilisee (im-lf) et utilisations associees
WO2002077239A1 (fr) * 2001-03-27 2002-10-03 Sumitomo Pharmaceuticals Company, Limited Polypeptides se liant au virus hcv
CA2485957A1 (fr) * 2002-11-29 2004-06-17 Nobuhiko Katunuma Inhibiteur de protease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 6 March 2002 (2002-03-06), "UI-E-CL1-aeu-g-09-0-UI.r1 UI-E-CL1 Homo sapiens cDNA clone UI-E-CL1-aeu-g-09-0-UI 5', mRNA sequence.", XP002372490, retrieved from EBI accession no. EM_EST:BM692087 Database accession no. BM692087 *
DATABASE EMBL 2 August 1999 (1999-08-02), NCI-CGAP: "wn82c05.x1 NCI_CGAP_Ut1 Homo sapiens cDNA clone IMAGE:2452328 3' similar to gb:M73700 LACTOTRANSFERRIN PRECURSOR (HUMAN);, mRNA sequence", XP002325825, retrieved from EBI, HINXTON UK Database accession no. AI920805 *
GRANGE P A ET AL: "Characterization of lactoferrin recognized by Kaposi sarcoma associated herpes virus 8, in human saliva", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 123, no. 6, December 2004 (2004-12-01), & 21ST FRENCH ANNUAL MEETING OF DERMATOLOGICAL RESEARCH; NICE, FRANCE; JUNE 11 -12, 2004, pages A99, XP008061565, ISSN: 0022-202X *
GRANGE PHILIPPE A ET AL: "Salivary lactoferrin is recognized by the human herpesvirus-8", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 124, no. 6, June 2005 (2005-06-01), pages 1249 - 1258, XP002371952, ISSN: 0022-202X *
SICILIANO ROSA ET AL: "Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 264, no. 1, 14 October 1999 (1999-10-14), pages 19 - 23, XP002325823, ISSN: 0006-291X *
VALENTI P ET AL: "Antiviral activity of lactoferrin-derived peptides", INTERNATIONAL CONGRESS SERIES; LACTOFERRUB: STRUCTURE, FUNCTION AND APPLICATIONS ELSEVIER SCIENCE B.V. {A}, SARA BURGERHARTSTRAAT 25, 1000 AE, AMSTERDAM, NETHERLANDS SERIES : INTERNATIONAL CONGRESS SERIES (ISSN 0531-5131), 2000, & 4TH INTERNATIONAL CONFERENCE ON LACTOFERRIN: STRUCTURE, FUNCTION AND APPLICATIONS; SAPPORO, JAPAN; MAY 18-22, 1999, pages 181 - 186, XP008045737, ISSN: 0-444-50317-X *
VAN DER STRATE B W A ET AL: "Antiviral activities of lactoferrin", ANTIVIRAL RESEARCH, vol. 52, no. 3, December 2001 (2001-12-01), pages 225 - 239, XP002325824, ISSN: 0166-3542 *

Also Published As

Publication number Publication date
FR2875501B1 (fr) 2008-02-29
FR2875501A1 (fr) 2006-03-24
WO2006032781A2 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
MX2007003906A (es) Metodos y composiciones para mejorar la produccion de proteinas recombinantes.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO2007011363A3 (fr) Proteines de fusion a domaine de liaison
WO2007047207A3 (fr) Inhibiteurs de la proteine activant la 5-lipoxygenase (flap)
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
MY154826A (en) Fusion protein capable of binding vegf
WO2005081911A3 (fr) Methodes et compositions pour le traitement et la prevention d'une infection par le vih au moyen de trim5$g(a)
TW200630356A (en) Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
WO2007056220A3 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
WO2004054607A3 (fr) Proteines therapeutiques stables
WO2004042083A3 (fr) Ligands d'acides nucleiques et leurs utilisations
WO2009048658A3 (fr) Peptide optimisé (dn81), inhibiteur d'infiltration du virus de la dengue
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
WO2007093848A3 (fr) Nouveaux polypeptides purifiés issus de helicobacter pylori
WO2006032781A3 (fr) Derives peptidiques , compositions et utilisations dans un traitement therapeutique de l’infection par un herpevirus
WO2006047728A3 (fr) Genes bmp et proteines de fusion
WO2005071067A3 (fr) Agents stabilisateurs d'origine non animale et leurs procedes de production
WO2010065536A3 (fr) Antigène-2 du stroma de la moelle osseuse recombinant dans le traitement de maladies auto-immunes
WO2002062964A3 (fr) Variants d'amine oxydase ap1
WO2001066709A3 (fr) Enzymes et utilisations les concernant
WO2002079222A3 (fr) Proteines de fusion pour le traitement specifique du cancer et de maladies auto-immunes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase